PARP Proteins, Antibodies, cDNA Clones Research Reagents

PARP1 (Poly(ADP-Ribose) Polymerase 1) is a protein coding gene located on human chromosome 1q42.12. PARP1 is also known as PARP, PPOL, ADPRT, ARTD1, ADPRT1, PARP-1, ADPRT 1 and pADPRT-1. The human PARP1 gene encodes a 113084 Da protein containing 1014 amino acids. The PARP1 protein is ubiquitously expressed in lymph node, appendix and other tissues. Among its related pathways are Signaling by GPCR and Telomere C-strand (Lagging Strand) Synthesis. PARP1 is related to protein kinase binding. PARP2 is an important paralog of PARP1 gene. PARP1 is associated with some diseases, including Diphtheria and Xeroderma Pigmentosum, Complementation Group A.

PARP Protein (2)

    PARP Antibody (8)

      PARP cDNA Clone (30)

      NM_001618.3

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_007415.2

      克隆载体 cDNA 产品

      In lentiviral vector

      PARP Lysate (2)

        PARP 分子背景

        Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrated to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors are thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.

        PARP 参考文献

        • Malanga M. et al., 1998, J Biol Chem. 273: 11839-11843.
        • Ariumi Y. et al., 1999, Oncogene. 18: 4616-4625.
        • Helleday T. et al., 2005, Cell Cycle. 4: 1176-1178.
        • Ahell I. et al., 2008, Nature. 451: 81-85.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.